Status:
COMPLETED
CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study
Lead Sponsor:
Liverpool John Moores University
Collaborating Sponsors:
Liverpool University Hospitals NHS Foundation Trust
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
Glycaemic control is an important aspect of Type 1 diabetes (T1D) management for diabetologists and patients alike. Evidence suggests continuous subcutaneous insulin infusion (CSII) is an effective me...
Detailed Description
Continuous subcutaneous insulin infusion (CSII) is a therapy for patients with Type-1 diabetes mellitus involving insulin administration via electronic pump. CSII has been shown to reduce HbA1c levels...
Eligibility Criteria
Inclusion
- Patients must reside in Liverpool or the surrounding areas.
- Patients must be ages over 18
- Patients must have Type 1 diabetes
- Patients must be using or pending the supply of an insulin pump.
Exclusion
- Patients must not live outside of Liverpool and the surrounding areas.
- Patients must not be aged under 18
Key Trial Info
Start Date :
December 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT02258932
Start Date
December 1 2013
End Date
October 1 2015
Last Update
February 19 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Liverpool and Broadgreen University Hospital
Liverpool, Merseyside, United Kingdom, L7 8XP